Michele Korfin
Director/Board Member bei ORGANOGENESIS HOLDINGS INC.
Vermögen: 424 932 $ am 31.03.2024
Aktive Positionen von Michele Korfin
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ORGANOGENESIS HOLDINGS INC. | Director/Board Member | 03.05.2022 | - |
Independent Dir/Board Member | 03.05.2022 | - | |
BioNJ, Inc.
BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services BioNJ, Inc. is based in Trenton, NJ. BioNJ, Inc. is a life sciences trade association with nearly 400 member companies. The company supports the discovery, development, and commercialization of therapies and cures that save and improve lives. BioNJ drives capital formation, fosters entrepreneurship, advocates for medical innovation, provides access to talent and education, and offers critical commercial resources. The company also serves as a clearinghouse for funding information and opportunities. The company was founded in 1994 by James J. Marino, Jayne C. Gershkowitz, Abraham Abuchowski. The CEO is Debbie Hart. | Director/Board Member | - | - |
Corporate Secretary | 13.02.2020 | - |
Karriereverlauf von Michele Korfin
Ehemalige bekannte Positionen von Michele Korfin
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
GAMIDA CELL LTD. | Chief Operating Officer | 01.08.2020 | 01.04.2024 |
TYME TECHNOLOGIES, INC. | Chief Operating Officer | 15.03.2019 | 01.01.2020 |
Corporate Officer/Principal | 15.10.2018 | 15.03.2019 | |
KITE PHARMA INC | Corporate Officer/Principal | 01.01.2016 | 01.07.2018 |
CELGENE | Corporate Officer/Principal | 01.01.2004 | 01.03.2016 |
Ausbildung von Michele Korfin
Rutgers State University of New Jersey | Undergraduate Degree |
Harvard Business School | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 7 |
Frankreich | 2 |
Israel | 2 |
Operativ
Corporate Officer/Principal | 3 |
Chief Operating Officer | 2 |
Director/Board Member | 2 |
Sektoral
Health Technology | 6 |
Consumer Services | 3 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
GAMIDA CELL LTD. | Health Technology |
ORGANOGENESIS HOLDINGS INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Tyme Technologies, Inc.
Tyme Technologies, Inc. Pharmaceuticals: MajorHealth Technology Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ. | Health Technology |
BioNJ, Inc.
BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services BioNJ, Inc. is based in Trenton, NJ. BioNJ, Inc. is a life sciences trade association with nearly 400 member companies. The company supports the discovery, development, and commercialization of therapies and cures that save and improve lives. BioNJ drives capital formation, fosters entrepreneurship, advocates for medical innovation, provides access to talent and education, and offers critical commercial resources. The company also serves as a clearinghouse for funding information and opportunities. The company was founded in 1994 by James J. Marino, Jayne C. Gershkowitz, Abraham Abuchowski. The CEO is Debbie Hart. | Commercial Services |
Kite Pharma, Inc.
Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
- Börse
- Insiders
- Michele Korfin
- Erfahrung